Development and Marketing Agreement Sample Contracts
RECITALSDevelopment and Marketing Agreement • September 13th, 2000 • Targeted Genetics Corp /Wa/ • Biological products, (no disgnostic substances) • Delaware
EXHIBIT 10.33 DEVELOPMENT AND MARKETING AGREEMENT ----------------------------------- This DEVELOPMENT AND MARKETING AGREEMENT is made and entered into as of this 12th day of March 1999 by and between OVERLAND R.C. 29, LLC, a California Limited...Development and Marketing Agreement • July 9th, 1999 • Inco Homes Corp • Operative builders
ContractDevelopment and Marketing Agreement • May 14th, 2003 • Intermune Inc • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
Development and marketing agreement for Paradise ultrasound-based renal denervation systemDevelopment and Marketing Agreement • July 9th, 2024
ReCor Medical announced the signing of a development and commercialization agreement, together with an additional investment, with Otsuka Holdings , a global healthcare group headquartered in Tokyo, Japan.
Development and marketing agreement for APAC productDevelopment and Marketing Agreement • June 27th, 2024
Aplagon and Cadila Pharmaceuticals announced a development and commercialization agreement for Aplagon’s lead APAC product. APACs are proprietary, locally acting, potent antithrombotic products, which target blood vessel wall injury.
DEVELOPMENT AND MARKETING AGREEMENTDevelopment and Marketing Agreement • May 1st, 2006 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Development and Marketing Agreement (this “Agreement”) is hereby entered into and effective as of February 22, 2006 (the “Effective Date”) by and between Spectrum Pharmaceuticals, Inc. (“Spectrum”), a Delaware corporation, with offices located at 157 Technology Drive, Irvine, California 92618 and Par Pharmaceutical, Inc. (“Par”), a Delaware corporation with offices located at 300 Tice Boulevard, Woodcliff Lake, New Jersey 07677. Spectrum and Par shall each be defined as a “Party” and together as the “Parties” under this Agreement.
ContractDevelopment and Marketing Agreement • August 13th, 2002 • Intermune Inc • Pharmaceutical preparations
Boehringer Ingelheim International GmbH - 55216 Ingelheim am Rhein InterMune Pharmaceuticals 3280 Bayshore Blvd Brisbane, CA 94005 U.S.A. Boehringer Ingelheim International GmbH
ContractDevelopment and Marketing Agreement • October 10th, 2014
Kyorin Pharmaceutical and R-Pharm Reach Agreement in Russia and neighboring nations for Activities Related to the Development and Marketing of Imidafenacin
For Immediate ReleaseDevelopment and Marketing Agreement • November 7th, 2011
Kyorin Pharmaceutical and Daiichi Sankyo Brasil Reach Agreement in Brazil for Activities Related to the Development and Marketing of Imidafenacin
EXHIBIT 10.31 DEVELOPMENT AND MARKETING AGREEMENT ----------------------------------- This DEVELOPMENT AND MARKETING AGREEMENT is made and entered into as of this 12th day of March 1999 by and between HARWOOD PALMDALE PARTNERS I, LP, a Limited...Development and Marketing Agreement • July 9th, 1999 • Inco Homes Corp • Operative builders
Development and Marketing Agreement —Between— Boehringer Ingelheim International GmbH and InterMune Pharmaceuticals, Inc. March 23, 2001Development and Marketing Agreement • May 15th, 2001 • Intermune Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 10.19Development and Marketing Agreement • December 30th, 1996 • Epitope Inc/Or/ • In vitro & in vivo diagnostic substances • California
WITNESSETHDevelopment and Marketing Agreement • November 14th, 1997 • United Homes Inc • General bldg contractors - residential bldgs • Illinois
Development and marketing agreement for ALN-PCS RNAi therapeutic programDevelopment and Marketing Agreement • February 8th, 2022 • New York
Milestones, US$m: 180 : sum of potential development and commercial milestone payments n/d : scaled double-digit royalties on global products sales of ALN-PCS
FIRST AMENDMENT TO THE DEVELOPMENT AND MARKETING AGREEMENTDevelopment and Marketing Agreement • March 14th, 2007 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • New York
This First Amendment (“Amendment”) to the Development and Marketing Agreement (“Agreement”) dated February 22, 2006, by and between Spectrum Pharmaceuticals, Inc. (“Spectrum”) and Par Pharmaceutical, Inc. (“Par”) is entered into and is effective as of November 10, 2006 (“First Amendment Effective Date”), hereinafter referred to as “Party” and, collectively, as “Parties.” Capitalized terms used but not defined herein shall have the meanings given them in the Agreement.
EXHIBIT 10.87 DEVELOPMENT AND MARKETING AGREEMENT ----------------------------------- This DEVELOPMENT AND MARKETING AGREEMENT is made and entered into as of this 21st day of October 1997 and between CAPITAL MUTUAL MORENO VALLEY, LLC., a California...Development and Marketing Agreement • March 31st, 1998 • Inco Homes Corp • Operative builders
Halliburton Company and Intelligent Inspection Corporation Sign Agreement To Deliver Robotic TechnologyDevelopment and Marketing Agreement • July 26th, 2019
DALLAS, April 30 /PRNewswire/ -- Halliburton Company (NYSE: HAL) and Intelligent Inspection Corporation (IIC) have signed a definitive agreement for the development, marketing, and delivery of robotic technology to the oil and gas industry. The new technology is expected to significantly reduce oil and gas operational costs, especially in deepwater regions like the Gulf of Mexico, Brazil, and West Africa.
Development and marketing agreement for flurpiridaz F 18Development and Marketing Agreement • July 8th, 2024
Lantheus Medical Imaging, Inc., a subsidiary of Lantheus Holdings, Inc. , and GE Healthcare announced the signing of a term sheet relating to the continued Phase III development and worldwide commercialization of flurpiridaz F 18, an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent that may improve the diagnosis of coronary artery disease (CAD).
San Donato Milanese (MI), 03 August 2020 - Versalis (Eni) and Forever Plast SpA, a leading Italian company in the recovery and recycling of post-consumer plastic at European level, have signed an agreement to develop and market a new range of solid...Development and Marketing Agreement • August 3rd, 2020
The new Versalis Revive® PS - Series Forever products, polystyrene-based compounds* containing up to 75% of recycled solid polystyrene, are able to meet the requirements of multiple applications such as thermal insulation, non-food packaging and household items.
RIN DEVELOPMENT and MARKETING AGREEMENTDevelopment and Marketing Agreement • April 29th, 2021
ContractDevelopment and Marketing Agreement • August 13th, 2002 • Intermune Inc • Pharmaceutical preparations
Boehringer Ingelheim International GmbH - 55216 Ingelheim am Rhein InterMune Pharmaceuticals 3280 Bayshore Blvd Brisbane, CA 94005 U.S.A. Boehringer Ingelheim International GmbH
MODIFICATION TO DEVELOPMENT AND MARKETING AGREEMENTDevelopment and Marketing Agreement • July 25th, 2008 • AngioGenex, Inc. • Communications services, nec
THIS MODIFICATIONAGREEMENT dated July 21, 2008 applies to the DEVELOPMENT AND MARKETING AGREEMENT (the "Agreement') made and entered into and effective as of December 15, 2003 by and between BioCheck, Inc., a California corporation ('BioCheck") and AngioGenex, Inc., a New York corporation ("Angio').
WITNESSETHDevelopment and Marketing Agreement • November 14th, 1997 • United Homes Inc • General bldg contractors - residential bldgs • Illinois
FIRST AMENDED AND RESTATED DEVELOPMENT AND MARKETING AGREEMENT by and between ZymoGenetics, Inc. and Ares Trading S.A. Amended and Restated as of: August 28, 2008 “[ * ]” = omitted, confidential material, which material has been separately filed with...Development and Marketing Agreement • November 5th, 2008 • Zymogenetics Inc • Biological products, (no disgnostic substances) • New York
This First Amended and Restated Development and Marketing Agreement (this “Restated Agreement”) is made as of the Effective Date by and between ZymoGenetics, Inc., a Washington corporation having its principal place of business at 1201 Eastlake Avenue East, Seattle, Washington 98102 (“ZGI”), and Ares Trading S.A., a Swiss corporation having offices at Zone Industrielle de l’Ouriettaz, 1170 Aubonne, Switzerland (“Merck Serono”), with respect to the following recitals:
For Immediate ReleaseDevelopment and Marketing Agreement • November 7th, 2011
Daiichi Sankyo Brasil and Kyorin Pharmaceutical Reach Agreement in Brazil for Activities Related to the Development and Marketing of Imidafenacin
Development and marketing agreement for RNA interference therapies for cardiovascular diseaseDevelopment and Marketing Agreement • June 26th, 2024